Terms: = Prostate cancer AND PSA AND Treatment
9425 results:
1. Salvage Radiotherapy PSMA PET/CT-guided in Men With psa Recurrence.
Tamburo M; Buffettino E; Pepe P; Marletta G; Pepe L; Cosentino S; Ippolito M; Pennisi M; Marletta F
Anticancer Res; 2024 May; 44(5):2205-2210. PubMed ID: 38677723
[TBL] [Abstract] [Full Text] [Related]
2. An Extracellular Matrix Overlay Model for Bioluminescence Microscopy to Measure Single-Cell Heterogeneous Responses to Antiandrogens in prostate cancer Cells.
Champagne A; Chebra I; Jain P; Ringuette Goulet C; Lauzier A; Guyon A; Neveu B; Pouliot F
Biosensors (Basel); 2024 Apr; 14(4):. PubMed ID: 38667168
[TBL] [Abstract] [Full Text] [Related]
3. [prostate cancer - a disease in transformation].
Bratt O
Lakartidningen; 2024 Apr; 121():. PubMed ID: 38661575
[TBL] [Abstract] [Full Text] [Related]
4. [Molecular subtypes provide possibilities for precision medicine in a advanced prostate cancer].
Wikström P; Bergh A; Josefsson A; Thysell E; Welén K
Lakartidningen; 2024 Apr; 121():. PubMed ID: 38656744
[TBL] [Abstract] [Full Text] [Related]
5. [Influence factors of erectile dysfunction in patients with localized prostate cancer after radical surgery].
Wang SH; Shi XQ; Ma MF; Jin XX; Zhao XD; Zhou YL; Gu YF; Hu J; Dong N; Dong J; Xu S
Zhonghua Nan Ke Xue; 2023 Dec; 29(12):992-999. PubMed ID: 38639951
[TBL] [Abstract] [Full Text] [Related]
6. [Application of 1470 nm semiconductor laser in the treatment of benign prostatic hyperplasia in ultra-aged patients].
Wu D; Yi XM; Wei HX; Zhang KX; Shi CJ; Shi XQ; Xu ZY; Fu D
Zhonghua Nan Ke Xue; 2023 Sep; 29(9):831-836. PubMed ID: 38639597
[TBL] [Abstract] [Full Text] [Related]
7. A pictorial view on false positive findings of
Dancheva Z; Chausheva S; Stoeva T; Dyankova M; Yordanova T; Chaushev B; Marinov R; Nikolov V; Abushev P; Todorov G; Dimitrova E; Klisarova A; Anakievski D
Hell J Nucl Med; 2024; 27(1):16-26. PubMed ID: 38629815
[TBL] [Abstract] [Full Text] [Related]
8. Predictive Value of Magnetic Resonance Imaging Radiomics Combined with Serum psa for the Extracapsular Extension of prostate cancer Prediction.
Wu J; Yu X; Zuo Z; Li J; Du F; Wang P; Jiang R
Arch Esp Urol; 2024 Mar; 77(2):217-223. PubMed ID: 38583015
[TBL] [Abstract] [Full Text] [Related]
9. The treatment landscape of nonmetastatic castrate resistant prostate cancer: A contemporary perspective.
Yanada BA; Homewood D; Dias BH; Ogluszko C; Corcoran NM
Urol Oncol; 2024 Jun; 42(6):175.e9-175.e18. PubMed ID: 38555235
[TBL] [Abstract] [Full Text] [Related]
10. Critical survival periods in prostate cancer in Sweden explored by conditional survival analysis.
Hemminki K; Zitricky F; Sundquist K; Sundquist J; Försti A; Hemminki A; Hemminki O
Cancer Med; 2024 Apr; 13(7):e7126. PubMed ID: 38545829
[TBL] [Abstract] [Full Text] [Related]
11. Exosomal prostate-Specific Membrane Antigen (PSMA) and Caveolin-1 as Potential Biomarkers of prostate cancer-Evidence from Serbian Population.
Matijašević Joković S; Korać A; Kovačević S; Djordjević A; Filipović L; Dobrijević Z; Brkušanin M; Savić-Pavićević D; Vuković I; Popović M; Brajušković G
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542507
[TBL] [Abstract] [Full Text] [Related]
12. Symptoms and quality of life among men starting treatment for metastatic castration-resistant prostate cancer - a prospective multicenter study.
Rönningås U; Holm M; Fransson P; Beckman L; Wennman-Larsen A
BMC Palliat Care; 2024 Mar; 23(1):80. PubMed ID: 38532425
[TBL] [Abstract] [Full Text] [Related]
13. The effect of dose-escalation radiotherapy with simultaneous-integrated-boost on the use of short-term androgen deprivation therapy in patients with intermediate risk prostate cancer.
Onal C; Guler OC; Erbay G; Elmali A
Prostate; 2024 Jun; 84(8):763-771. PubMed ID: 38528236
[TBL] [Abstract] [Full Text] [Related]
14. psa-density, DRE, and PI-RADS 5: potential surrogates for omitting biopsy?
Falkenbach F; Ambrosini F; Kachanov M; Ortner G; Maurer T; Köhler D; Beyersdorff D; Graefen M; Budäus L
World J Urol; 2024 Mar; 42(1):182. PubMed ID: 38506941
[TBL] [Abstract] [Full Text] [Related]
15. Extreme-hypofractionated RT with concomitant boost to the DIL in PCa: a 5-year update on oncological and patient-reported outcomes for the phase II trial "GIVE ME FIVE".
Marvaso G; Corrao G; Repetti I; Lorubbio C; Bellerba F; Zaffaroni M; Vincini MG; Zerini D; Alessi S; Luzzago S; Mistretta FA; Fodor C; Cambria R; Cattani F; Ceci F; Musi G; De Cobelli O; Zilli T; Gandini S; Orecchia R; Petralia G; Jereczek-Fossa BA
World J Urol; 2024 Mar; 42(1):169. PubMed ID: 38492078
[TBL] [Abstract] [Full Text] [Related]
16. Evaluating relugolix for the treatment of prostate cancer in real-world settings of care: the OPTYX study protocol.
Spratt DE; Dorff T; McKay RR; Lowentritt BH; Fallick M; Gatoulis SC; Flanders SC; Ross AE
Future Oncol; 2024 Apr; 20(12):727-738. PubMed ID: 38488039
[TBL] [Abstract] [Full Text] [Related]
17. A study on the impact of marital status on the survival status of prostate cancer patients based on propensity score matching.
Chen Q; Zhu X; Hu Y; Chen Y; Dai R; Li J; Zhuang J; Lin Y; Zeng Y; You L; Zeng Y; Huang Q
Sci Rep; 2024 Mar; 14(1):6162. PubMed ID: 38485743
[TBL] [Abstract] [Full Text] [Related]
18. Triggers for transition from active surveillance to radical treatment of prostate cancer 2008-2020 - a case-control study.
Ahlberg M; Garmo H; Stattin P; Gedeborg R; Edlund C; Holmberg L; Bill-Axelson A
Scand J Urol; 2024 Mar; 59():63-69. PubMed ID: 38482602
[TBL] [Abstract] [Full Text] [Related]
19. Nadir prostate-specific antigen after salvage cryotherapy as a potential prognostic factor for oncologic outcomes.
Carbonell E; Mercader C; Sureda J; Gutiérrez A; Muñoz J; Gallardo E; Feltes N; Mases J; Valduvieco I; Vilaseca A; Franco A; Alcaraz A; Musquera M; Ribal MJ
World J Urol; 2024 Mar; 42(1):133. PubMed ID: 38478102
[TBL] [Abstract] [Full Text] [Related]
20. Hypofractionated radiation therapy combined with androgen deprivation therapy for high-risk localized prostate cancer.
Lee TH; Pyo H; Yoo GS; Jeon SS; Seo SI; Jeong BC; Jeon HG; Sung HH; Kang M; Song W; Chung JH; Bae BK; Park W
J Med Imaging Radiat Oncol; 2024 Apr; 68(3):333-341. PubMed ID: 38477380
[TBL] [Abstract] [Full Text] [Related]
[Next]
